The White House’s Framework for Nucleic Acid Synthesis Screening is pushing companies to reevaluate their biosecurity process to balance compliance, costs, and the customer experience. We created a resource to help companies select the right approach for screening including a look at manual approaches, open-source tools, and commercial solutions. Learn more about requirements and solutions for: - Sanctions and watchlist monitoring - DNA and RNA sequence screening - Trade compliance - Researcher identity verification - Order and compliance management - Integration with internal tools like ERP, CRM, and MES Making the right choice can significantly impact turnaround times, revenue, costs, and noncompliance risk.
Aclid
Software Development
New York, NY 1,125 followers
Helping scientists build safer and better biomanufactured products
About us
Aclid helps scientists build safer and better biomanufactured products. The world's leading biotech manufacturers and governments rely on Aclid's security and safety products for responsible research.
- Website
-
https://aclid.bio
External link for Aclid
- Industry
- Software Development
- Company size
- 2-10 employees
- Headquarters
- New York, NY
- Type
- Privately Held
Locations
-
Primary
Get directions
New York, NY, US
Employees at Aclid
Updates
-
We’re excited to share this critical piece at the intersection of AI, synthetic biology, and biosecurity. By supporting safe and responsible use of advances in AI and genetic engineering, we’re accelerating adoption and breakthroughs in biology.
Addressing Biosecurity Challenges in the Age of Generative AI We’re living through an exciting time in biology accelerated by AI breakthroughs. Last year, as we prepared for an international workshop on AI and biosecurity, Bruce Wittmann and I explored how AI tools could be used to redesign toxic proteins. Using AI-powered protein design tools, we generated designs for synthetic homologs—modified versions of toxic proteins with altered amino acid sequences engineered to potentially retain the structure and function of the originals. Although we stayed in the digital realm, our investigation revealed a critical vulnerability: AI tools can create synthetic variants of toxic proteins that could bypass existing screening systems. Recognizing the potential severity of this biosecurity threat—comparable to a “zero-day” vulnerability in cybersecurity—we launched the Paraphrase Project, a confidential yearlong collaboration with a fabulous cross-sector team to address this pressing issue. Our team conducted intensive “bioscience red teaming” to better understand this challenge and develop enhancements to DNA synthesis screening tools. We confidentially shared our findings and mitigations with the International Gene Synthesis Consortium earlier this year. Today, we published our paper, Toward AI-Resilient Screening of Nucleic Acid Synthesis Orders: Process, Results, and Recommendations, that provides details about our successful pursuit of an AI-resiliency “patch” for DNA synthesis screening tools. Our work highlights the dual-use nature of emerging technologies and the importance of staying vigilant and taking proactive measures to ensure their safe and responsible use. By sharing our approach and findings, we aim to strengthen safeguards while unlocking AI’s immense potential for good. Bruce Wittmann Tessa Alexanian Craig Bartling Jake Beal Adam Clore James Diggans Kevin Flyangolts Bryan Gemler Nicole Wheeler Sheng Lin-Gibson Gopal Sarma, MD, PhD Steph Guerra, PhD Jason Matheny T. Greg McKelvey Jr. Lynda Stuart MD PhD Brad Malin Jaime Yassif Piers Millett Paul Friedrichs Frances Arnold Arati Prabhakar Sarah McGee Jessica Young Natasha Crampton Kevin Esvelt Daniel Kluttz Kevin Scott Satya Nadella Brad Smith
Toward AI-Resilient Screening of Nucleic Acid Synthesis Orders: Process, Results, and Recommendations
biorxiv.org
-
The biotechnology world is embracing a powerful tool from cybersecurity: red teaming. To enhance biosecurity, stress tests are challenging the screening systems of DNA and RNA synthesis providers. Recent findings caught the attention of both the scientific community and policymakers. In 2023, the White House issued an Executive Order on AI that called for stress testing of nucleic acid synthesis procurement screening. For providers of synthetic nucleic acids, the message is clear: Adopt robust screening protocols or risk failing these tests. It's not just about compliance - it’s about building trust, demonstrating commitment to safety, and safeguarding reputation. Companies that implement stringent screening protocols will not only mitigate risks but also strengthen their industry position.
Red teaming in biosecurity
aclid.bio
-
We're hosting a second session of our deep dive with #RTXBBN on the U.S. government’s “Framework for Nucleic Acid Synthesis Screening”. Learn more about the new screening requirements for providers of all DNA/RNA including CROs, CDMOs, and gene and oligo synthesis services. Hear from thought leaders from Battelle, International Biosecurity and Biosafety Initiative for Science (IBBIS), National Institute of Standards and Technology (NIST), U.S. Department of Health and Human Services (HHS) and Twist Bioscience. Register here: https://lnkd.in/eqbikv42
-
-
🧬 Nucleic acid screening certification guide If you're providing genes, oligos, viral vectors, or plasmids to your customers, you'll want to familiarize yourself with the White House's Framework for Nucleic Acid Synthesis Screening. 📚 In anticipation of the October 2024 deadline, we put together a guide walking you through the entire process: https://lnkd.in/ee9PRJmS
Nucleic acid screening certification guide
aclid.bio
-
We're hosting a deep dive with #RTXBBN on the U.S. government’s “Framework for Nucleic Acid Synthesis Screening”. Learn more about the new screening requirements for providers of all DNA/RNA including CROs, CDMOs, and gene and oligo synthesis services. Hear from thought leaders from Battelle, International Biosecurity and Biosafety Initiative for Science (IBBIS), National Institute of Standards and Technology (NIST), National Security Council, The White House and Twist Bioscience. Register here: https://lnkd.in/eqbikv42
-
-
Aclid reposted this
🗞️ 2048 Ventures Portfolio Company News: The US Is Cracking Down on Synthetic DNA https://lnkd.in/gnx4tpZH Aclid // 2048 Ventures // #startups // #VC
The US Is Cracking Down on Synthetic DNA
wired.com
-
Today, the White House issued new screening requirements for providers of synthetic DNA and RNA. If you're interested in a quick summary of the updates, we wrote about it here: https://lnkd.in/eUMePMWN
Framework for Nucleic Acid Synthesis Screening | OSTP | The White House
whitehouse.gov
-
We're hosting a night of apps and drinks with NinthBio on May 6th from 6:00 pm to 8:00 pm. Join us for the 2024 SynBioBeta kickoff! Register today! https://lu.ma/tn1q7l9i
Aclid x NinthBio Drinks 🍸 · Luma
lu.ma
-
🔬 Synthesis and Cloning Providers — Screening Is a Competitive Advantage The White House is issuing new legislation that mandates screening certification for vendors working with government agencies, academic institutions, and federal contractors. ➡️ Leading providers like Integrated DNA Technologies, Thermo Fisher Scientific, and Twist Bioscience are already using screening to get ahead of the curve. 🦖 Don't risk disruptions to your customer contracts and workflows - start getting certified now. 📚 To learn more about the new standards, the implications and opportunities, and how to get started with an automated screening tool like Aclid see the link below: 📝 https://lnkd.in/eUMePMWN
Screening Is a Competitive Advantage
aclid.bio